Amneal Pharmaceuticals, Inc. Class A Common Stock

AMRXNASDAQUSD
17.92 USD
0.14 (0.79%)AT CLOSE (11:59 AM EDT)
17.83
0.09 (0.52%)
POST MARKET (AS OF 07:32 PM EDT)
Post Market
AS OF 07:32 PM EDT
17.83
0.09 (0.52%)
🟢Market: OPEN

Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX) trades at $17.83 per share. The technical outlook is "Buy" and the fundamental picture shows "Neutral". Key drivers include exceptional Return on Equity (476.5%) and a bullish Golden Cross on the moving averages. AMRX is fairly valued relative to its sector peers based on current multiples.

Technical & fundamental data as of Aug 25, 2026.

Open?$17.78
High?$17.96
Low?$17.61
Prev. Close?$17.78
Volume?1.1M
Avg. Volume?1.8M
VWAP?$17.76
Rel. Volume?0.62x
Bid / Ask
Bid?$17.90 × 200
Ask?$17.94 × 300
Spread?$0.04
Midpoint?$17.92
Valuation & Ratios
Market Cap?6.2B
Shares Out?319.4M
Float?169.5M
Float %?53.2%
P/E Ratio?39.35
P/B Ratio?187.52
EPS?$0.45
Dividend?0.06%
Ex-Dividend?N/A
News
Profile
Amneal Pharmaceuticals Inc is a pharmaceutical company operating in the U.S., India, and Ireland. With three reportable segments; Affordable Medicines, Specialty, and AvKARE. It develops, manufactures, and distributes a diverse portfolio of essential medicines. The Affordable Medicines segment, which derives maximum revenue, focuses on a wide range of dosage forms and delivery systems, contributing significantly to revenues. The Specialty segment promotes proprietary branded pharmaceuticals, particularly targeting the central nervous system and endocrine disorders. The AvKARE segment provides pharmaceuticals and medical products to governmental agencies, specializing in re-packaging and wholesale distribution, with a focus on offering consistent care and pricing to qualified entities.
Employees
8.5K
Market Cap
6.2B
Industry
PHARMACEUTICAL PREPARATIONS
Listed
2018-05-07
Technical OutlookBuy
Strong SellNeutralStrong Buy
Long-Term (Tide)? Bullish(+2/3)
Medium-Term (Wave)? Neutral(0/3)
Short-Term (Ripple)? Bullish(+1/3)
MA Alignment?Mixed
Full Technical Analysis →
Fundamental OutlookNeutral
Strong SellNeutralStrong Buy
F-Score?
77
Z-Score?
51
Momentum?
62
Short Sent.?
44
Piotroski F-Score?6/9Mixed
Altman Z-Score?2.42Grey
Confidence?73%Moderate
Full Fundamental Analysis →
Short InterestElevated
Short % of Float?5.61%Elevated
Short Interest?9.5M
Days to Cover?4.9
Free Float169.5M
Avg Daily Volume1.9M
Settlement Date2026-08-14
Financial Health
Current Ratio?2.20Strong
Quick Ratio?1.44Adequate
Cash Ratio?0.14Low
Debt/Equity?80.86High
ValuationFAIRLY VALUEDvs 1 peers + S&P 500
Score
61/100
P/E?
Peers
100
S&P
18
39.4PRICEY
P/B?
Peers
100
S&P
3
187.52HIGH
P/S?
Peers
100
S&P
67
1.99CHEAP
P/FCF?
Peers
100
S&P
12
46.8PRICEY
EV/EBITDA?
Peers
100
S&P
62
13.1FAIR
EV/Sales?
Peers
100
S&P
63
2.80CHEAP
Returns & Efficiency
ROE?
Peers
50
S&P
97
476.5%STRONG
ROA?
Peers
50
S&P
38
4.2%FAIR
Cash Flow & Enterprise
FCF?$132.5M
Enterprise Value?$8.7B
Fundamentals ratios updated end of day